Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Parker, C. C. [et al]
Sheehan, Denise J
RightsArchived with thanks to Lancet (London, England). This is an Open Access article under the CC BY 4.0 license.
MetadataShow full item record
Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.